The Performance of Novo Nordisk’s Premix and Fast-Acting Insulin
In the first quarter, Novo Nordisk’s (NVO) premix insulin generated net revenues of 2.64 billion Danish kroner compared to 2.86 billion Danish kroner in the first quarter of 2017, which reflected an ~8.0% YoY (year-over-year) decline.